About the AIR-NET Trial
The AIR-NET trial is exploring whether medications with anti-inflammatory properties can improve the health of people with bronchiectasis.
Participants in the trial will either:
- Receive one of the trial medications, or
- Continue with their usual bronchiectasis care, without any additional trial medication.
Each participant will only receive one treatment approach during the trial.
The medications being used are already available through the NHS for other conditions. They have been in use for many years, are generally well tolerated, and have been shown to reduce inflammation in the lungs.
Two key eligibility criteria, along with other inclusion requirements, are: A confirmed diagnosis of bronchiectasis on a CT scan (in one or more lobes) & Regular daily sputum production
For more detail, please visit Trial Information | Air-Net
